440 results
Randomised trials: substudies and extended follow-up - A quick update
15 May 2024 – From EuroPCR 2024
This session provides a quick update on various randomised trials, including substudies and extended follow-up data. It covers insights on bifurcation stenting, the symptom-stratified analysis of ORBITA-2, the impact of completeness of revascularisation on clinical outcomes from REVIVED-BCIS2, cost-effectiveness of CABG vs. PCI from FAME 3,...
PCI complications: device-related issues, perforations and other unexpected events
15 May 2024 – From EuroPCR 2024
This session focuses on the management of various complications that can occur during percutaneous coronary intervention (PCI), including device-related issues, perforations, and other unexpected events. Attendees will learn from case presentations and discussions on strategies to identify, mitigate, and manage these complications, with a focus on...
DCB PCI for de novo lesions: when and how?
15 May 2024 – From EuroPCR 2024
In this session, you will learn how to optimally perform DCB PCI, identify which lesions are best suited for this approach, and understand when it's necessary to switch from DCB to stent PCI. The session also features a debate on whether DCB-PCI should be the first...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
An image is worth a 1,000 words
15 May 2024 – From EuroPCR 2024
Make your life easier with imaging during primary PCI for acute coronary syndrome
15 May 2024 – From EuroPCR 2024
This session features selected EuroPCR 2024 Clinical Case submissions highlighting the use of imaging modalities, such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS), during primary percutaneous coronary interventions (PCI) for acute coronary syndrome. Experts will present and discuss challenging cases, demonstrating how the integration...
The ARC consensus on DCB - evidence-based DCB technology
15 May 2024 – From EuroPCR 2024
In this replay, discover why DCBs are essential in treating de novo CAD, the importance of optimal lesion preparation for long-term success, and how future trials will focus on treatment strategies rather than device comparisons, highlighting the need for further research.
Artificial intelligence-powered quantification of coronary physiology and vulnerable plaque: opportunities for novel treatment options
15 May 2024 – From EuroPCR 2024
In this session, uncover new data on Murray-law based quantitative flow ratio (muFR) assessment, providing a comprehensive understanding of PCI outcomes from a single angiographic view, explore the innovative application of artificial intelligence in identifying vulnerable plaque and assessing hemodynamic stenosis significance through the analysis of...
Complex PCI in ACS patient with high bleeding risk: optimise the strategy
15 May 2024 – From EuroPCR 2024
Watch this session for insights into managing acute coronary syndrome patients with multivessel disease, updates on treatment approaches, comparing FULL RESVAC with previous trials like COMPLETE or FIRE, for example, and information on ongoing trials such as FRAMI-AMI 2 and 3. Explore the LIVE case presentation...
Second generation biolimus drug-coated balloon in clinical practice
15 May 2024 – From EuroPCR 2024
Discover the potential applications of the new biolimus-coated balloon in treating de novo large vessel lesions, explore its effectiveness in addressing ISR based on findings from the BIO ASCEND ISR study, and uncover insights into the safety and feasibility of BA9 DCB in treating small vessel,...
